{"resourceType": "Evidence", "title": "Evidence for Results for Adverse event free and hypertension control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan", "relatesTo": [{"type": "part-of", "targetReference": {"reference": "Composition/375280", "type": "Composition", "display": "Outcome Measure Report for QUARTET USA Trial"}}], "variableDefinition": [{"variableRole": "population", "observed": {"display": "the study group"}}, {"variableRole": "exposure", "observed": {"reference": "EvidenceVariable/375183", "type": "EvidenceVariable", "display": "GroupAssignment: Quadpill vs. Candesartan"}}, {"variableRole": "outcome", "observed": {"reference": "EvidenceVariable/375278", "type": "EvidenceVariable", "display": "Adverse event free and hypertension control at 12 weeks"}}], "id": "397478", "statistic": [{"statisticType": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000182", "display": "odds ratio"}]}, "quantity": {"value": 0.83}, "numberAffected": 13, "sampleSize": {"numberOfParticipants": 62, "knownDataCount": 53, "extension": [{"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/number-analyzed", "valueUnsignedInt": 53}]}, "attributeEstimate": [{"type": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000196", "display": "confidence interval"}]}, "level": 0.95, "range": {"low": {"value": 0.22}, "high": {"value": 3.16}}}, {"type": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000700", "display": "p-value"}]}, "quantity": {"value": 0.775}}]}], "text": {"status": "generated", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Title: </b>Evidence for Results for Adverse event free and hypertension control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan</p><p><b>Variable in role of population: </b>the study group</p><p><b>Variable in role of exposure: </b>GroupAssignment: Quadpill vs. Candesartan</p><p><b>Variable in role of outcome: </b>Adverse event free and hypertension control at 12 weeks</p><p><b>Statistic: </b>odds ratio (coded as: STATO:0000182 from https://fevir.net/sevco) 0.83</p></div>"}, "meta": {"versionId": "4", "lastUpdated": "2025-09-13T18:19:04.761Z"}, "url": "https://fevir.net/resources/Evidence/397478", "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "system": "https://fevir.net/FOI", "value": "397478", "assigner": {"display": "Computable Publishing LLC"}}], "publisher": "Computable Publishing LLC", "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "contact": [{"telecom": [{"system": "email", "value": "support@computablepublishing.com"}]}], "author": [{"name": "Brian S. Alper, MD, MSPH"}], "citeAs": "Evidence for Results for Adverse event free and hypertension control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan [Database Entry: FHIR Evidence Resource]. Contributors: Brian S. Alper, MD, MSPH [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 397478. Revised 2025-09-13. Available at: https://fevir.net/resources/Evidence/397478. Computable resource at: https://fevir.net/resources/Evidence/397478#json.", "status": "active", "name": "Evidence_for_Results_for_Adverse_event_free_and_hypertension_control_at_12_weeks_in_GroupAssignment_Quadpill_vs_Candesartan", "description": "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide."}